Literature DB >> 22014109

Neutrophil proteinase 3 induces diabetes in a mouse model of glucose tolerance.

Suyoung Bae1, Jida Choi, Jaewoo Hong, Hyunjhung Jhun, Kwangwon Hong, Taebong Kang, Keeho Song, Sangmin Jeong, Hokee Yum, Soohyun Kim.   

Abstract

Type 1 diabetes is considered to be an autoimmune disease in which T cells attack pancreatic islet cells. Impaired glucose tolerance with type 2 diabetes has been classified as an obesity-associated metabolic syndrome. However, recent studies have revealed that type 2 diabetes is an autoinflammatory disease due to an imbalance of inflammatory cytokine production and related molecular components that cause inflammation. Insulin-like growth factor (IGF) and the insulin-like growth factor-binding protein-3 (IGFBP3) system are known to be involved in the development of experimental diabetic nephropathy, and urinary IGFBP3 protease activity has been observed in patients with type 2 diabetes. A serine protease was found to be responsible for the proteolytic activity in diabetic urine; however, the identity of the precise enzyme remains unknown. We investigated neutrophil proteinase 3 (PR3) to see whether it has specific enzymatic activity associated with insulin-like growth factor-1 and IGFBP3. In our study, both molecules were sufficiently degraded, which leads us to believe that PR3 may induce insulin resistance in the mouse model utilized. In addition, we found that PR3 in the urine of diabetic patients similarly affects insulin resistance. Moreover, PR3-immunized mice had an increase in glucose clearance due to inhibition of PR3 activity. As such, PR3 can be considered as an inflammatory enzyme directly linking inflammation to type 2 diabetes through downregulation of insulin-like growth factor-1/IGFBP3.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014109     DOI: 10.3109/07435800.2011.620579

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  7 in total

1.  A carbon nanotube toxicity paradigm driven by mast cells and the IL-₃₃/ST₂ axis.

Authors:  Pranita Katwa; Xiaojia Wang; Rakhee N Urankar; Ramakrishna Podila; Susana C Hilderbrand; Robert B Fick; Apparao M Rao; Pu Chun Ke; Christopher J Wingard; Jared M Brown
Journal:  Small       Date:  2012-07-06       Impact factor: 13.281

Review 2.  IL-1 Family Cytokine Pathways Underlying NAFLD: Towards New Treatment Strategies.

Authors:  Andreea-Manuela Mirea; Cees J Tack; Triantafyllos Chavakis; Leo A B Joosten; Erik J M Toonen
Journal:  Trends Mol Med       Date:  2018-04-14       Impact factor: 11.951

3.  Proteases and protease inhibitors of urinary extracellular vesicles in diabetic nephropathy.

Authors:  Luca Musante; Dorota Tataruch; Dongfeng Gu; Xinyu Liu; Carol Forsblom; Per-Henrik Groop; Harry Holthofer
Journal:  J Diabetes Res       Date:  2015-03-19       Impact factor: 4.011

4.  PR3 levels are impaired in plasma and PBMCs from Arabs with cardiovascular diseases.

Authors:  Abdelkrim Khadir; Dhanya Madhu; Sina Kavalakatt; Preethi Cherian; Monira Alarouj; Abdullah Bennakhi; Jehad Abubaker; Ali Tiss; Naser Elkum
Journal:  PLoS One       Date:  2020-01-14       Impact factor: 3.240

Review 5.  Latent Autoimmune Diabetes in Adults (LADA): From Immunopathogenesis to Immunotherapy.

Authors:  Jingyi Hu; Rong Zhang; Hailan Zou; Lingxiang Xie; Zhiguang Zhou; Yang Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-21       Impact factor: 6.055

6.  Activation of proteinase 3 contributes to Non-alcoholic Fatty Liver Disease (NAFLD) and insulin resistance.

Authors:  Erik J M Toonen; Andreea-Manuela Mirea; Cees J Tack; Rinke Stienstra; Dov B Ballak; Janna A van Diepen; Anneke Hijmans; Triantafyllos Chavakis; Wim H Dokter; Christine T N Pham; Mihai G Netea; Charles A Dinarello; Leo A B Joosten
Journal:  Mol Med       Date:  2016-05-24       Impact factor: 6.354

7.  Abnormal Peripheral Neutrophil Transcriptome in Newly Diagnosed Type 2 Diabetes Patients.

Authors:  Qiuqiu Lin; Wenzhi Zhou; Yanfei Wang; Juan Huang; Xiaoyan Hui; Zhiguang Zhou; Yang Xiao
Journal:  J Diabetes Res       Date:  2020-04-22       Impact factor: 4.011

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.